Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

References

• Vickers M, Jackson G, Taylor P. The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation. Leukemia 2000;14:722–726.
   PubMed Web of Science ®Google Scholar
• Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002. Cancer Causes Control 2008;19:379–390.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Grimwade D, Solomon E, et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999;93:4131–4143.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999;94:1192–1200.
   PubMed Web of Science ®Google Scholar
• Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009;106:3342–3347.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009;27:504–510.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875–1891.
   PubMed Web of Science ®Google Scholar
• Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 2011;29:2753–2757.
   PubMed Web of Science ®Google Scholar
• Latagliata R, Petti MC, Fenu S, et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002;99:822–824.
   PubMed Web of Science ®Google Scholar
• Lobe I, Rigal-Huguet F, Vekhoff A, et al. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia 2003;17:1600–1604.
   PubMed Web of Science ®Google Scholar
• Ogasawara T, Yasuyama M, Kawauchi K. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2). Am J Hematol 2005;79:136–141.
   PubMed Web of Science ®Google Scholar
• Panizo C, Patino A, Lecumberri R, et al. Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: clinical and genetic features of two cases. Cancer Genet Cytogenet 2003;143:178–181.
   PubMed Web of Science ®Google Scholar
• Zompi S, Viguie F. Therapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemia. Leuk Lymphoma 2002;43:275–280.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Gonzalez JD, Gonzalez J, et al. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy. J Clin Oncol 2010;28:3872–3879.
   PubMed Web of Science ®Google Scholar
• Ades L, Guerci A, Raffoux E, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood 2010;115:1690–1696.
   PubMed Web of Science ®Google Scholar
• Szotkowski T, Jarosova M, Faber E, et al. Precursor T-lymphoblastic lymphoma as a secondary malignancy in a young patient after successful treatment of acute promyelocytic leukemia. Onkologie 2009;32:513–515.
   PubMed Web of Science ®Google Scholar
• Huang FS, Zwerdling T, Stern LE, et al. Renal cell carcinoma as a secondary malignancy after treatment of acute promyelocytic leukemia. J Pediatr Hematol Oncol 2001;23:609–611.
   PubMed Web of Science ®Google Scholar
• Pagana L, Pulsoni A, Tosti ME, et al. Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia. Br J Haematol 2001;112: 109–117.
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Pedersen M, Roulston D, et al. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995;86:3542–3552.
   PubMed Web of Science ®Google Scholar
• Chen SJ, Zhou GB, Zhang XW, et al. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 2011;117:6425–6437.
   PubMed Web of Science ®Google Scholar
• Andre M, Henry-Amar M, Blaise D, et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998;92:1933–1940.
   PubMed Web of Science ®Google Scholar
• Biti G, Cellai E, Magrini SM, et al. Second solid tumors and leukemia after treatment for Hodgkin’s disease: an analysis of 1121 patients from a single institution. Int J Radiat Oncol Biol Phys 1994;29:25–31.
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, Douglas AJ, Hudson GV, et al. Risk of second primary cancers after Hodgkin’s disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ 1992;304:1137–1143.
   PubMed Web of Science ®Google Scholar
• Tarbell NJ, Gelber RD, Weinstein HJ, et al. Sex differences in risk of second malignant tumours after Hodgkin's disease in childhood. Lancet 1993;341:1428–1432.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013;369:111–121.
   PubMed Web of Science ®Google Scholar